Quantcast

Latest R-Tech Ueno Ltd. Stories

2011-01-24 03:43:00

TOKYO, Jan. 24, 2011 /PRNewswire/ -- R-Tech Ueno, Ltd. is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia (note 1) was completed by January 21, 2011. Our company focuses on the area of no topical prescription drug in the market of androgenetic alopecia treatment and has developed a new topical drug. The Phase 2a clinical study of RK-023 for androgenetic alopecia treatment was performed in 48 patients with mild-to-moderate androgenetic alopecia,...

2010-08-16 03:00:00

TOKYO, Aug. 16 /PRNewswire/ -- R-Tech Ueno, Ltd., together with Sucampo Pharmaceuticals, Inc. ("Sucampo") and Sucampo AG ("SAG"), has requested arbitration against Takeda Pharmaceutical Co. Ltd. ("Takeda"). R-Tech Ueno supplies Amitiza (TM) Capsules to Takeda pursuant to agreements with Takeda and Sucampo. On March 12, 2010, Sucampo submitted for filing with the International Court of Arbitration, International Chamber of Commerce, a Request for Arbitration against Takeda. In that...

2010-07-15 04:29:00

TOKYO, July 15 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 15 the completion of the Phase II clinical study on the ophthalmic solution UF-021 (product name Ocuseva (TM)) under development as a therapeutic drug for retinitis pigmentosa (Note 1). Below is a summary of the detailed results of the study. - Description - The Phase II clinical study ("this study" hereafter) on the ophthalmic solution UF-021 (product name Ocuseva (TM)) for retinitis pigmentosa, a refractory disease for...

2010-06-10 04:00:00

TOKYO, June 10 /PRNewswire/ -- Sucampo Pharmaceuticals, Inc. (Sucampo) announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation (CIC) in Japanese patients has been completed (See Sucampo release dated June 8, 2010). R-Tech Ueno has an agreement with Sucampo Pharma Ltd. (SPL), a wholly owned subsidiary of Sucampo, under which it has the exclusive right to manufacture and supply lubiprostone (marketed as AMITIZA...

2010-05-06 05:54:00

TOKYO, May 6 /PRNewswire/ -- The Sanda factory of R-Tech Ueno, Ltd. has received notice from the U.S. Food and Drug Administration (FDA) that its facility has been classified as acceptable for the production of pharmaceuticals by meeting compliance with U.S. cGMP regulations (see the note below). The FDA inspected the Sanda factory in December 2009. By passing this inspection, Rescula® Eye Drops (unoprostone isopropyl eye drops) manufactured at this factory may be exported...

2009-10-06 04:47:00

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1). Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of...

2009-08-25 01:30:00

TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed. We submitted the notification of the clinical trial in August 2008. Enrollment in the phase 2 study began at six clinical sites in late December 2008 and was completed on August 3, 2009. The clinical study has progressed with...

2009-07-31 01:25:00

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows. The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities. 1. Development code UF-021 (eye diseases) The item in question is isopropyl...

2009-07-21 01:27:00

TOKYO, July 21 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 17 that as a phase 1 clinical study on the new compound RK-023 that is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed. The phase 1 clinical study of RK-023 consisted of a patch test (open, closed, photo-patch test), single-dose study and 5-day repeated-dose study. Since no serious adverse event occurred in each test, RK-023 seems to...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related